Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light

Submitted by admin on February 19, 2019 - 7:48pm
Source: 
Endpoints
News Tags: 
Merck
Keytruda
clinical trials
liver cancer
Headline: 
Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light
snippet: 

In a rare setback, Merck has suffered a key Phase III failure for Keytruda that could put a crimp in its sales prospects.

Do Not Allow Advertisers to Use My Personal information